Large Caps To Lead China’s Outbound Pharma M&A
This article was originally published in PharmAsia News
China’s large-cap pharmaceutical groups have been actively scouting for overseas M&A deals in recent years, with the aims of acquiring advanced technology and bigger global market shares. These cash-rich players’ interest in outbound investment is set to remain high, experts predict.
You may also be interested in...
With overseas revenues rising sharply in the first half of 2017, Fosun Pharma expects to build on its global investment strategy at a fast pace, striking more deals to acquire products and companies from developed markets.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.